Skip to main content
Erschienen in: Journal of Neuro-Oncology 2/2011

01.06.2011 | Laboratory Investigation - Human/Animal Tissue

The detection of CMV pp65 and IE1 in glioblastoma multiforme

verfasst von: Kenneth G. Lucas, Lei Bao, Richard Bruggeman, Kimberly Dunham, Charles Specht

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Glioblastoma multiforme (GBM) is a highly lethal brain tumor affecting children and adults, with the majority of affected individuals dying from their disease by 2 years following diagnosis. Other groups have reported the association of cytomegalovirus (CMV) with GBM, and we sought to confirm these findings in a large series of patients with primary GBM from our institution. Immunohistochemical analysis of paraffin embedded tissue sections was performed on 49 newly diagnosed GBM tumors, the largest series reported to date. We confirmed the presence of CMV pp65 on 25/49 (51%) and of IE1 on 8/49 (16%) of these tumors. While pp65 and IE1 are generally found in the nucleus of cells that are permissibly infected by CMV, GBM in this series had mostly cytoplasmic staining, with only 16% having nuclear staining for one or both of these antigens. We infected GBM cell lines with a laboratory strain of CMV, and found that most of the staining was cytoplasmic, with some perinuclear localization of IE1. To test the potential for CMV infected GBM cells to be recognized by CMV pp65 and IE1 specific cytotoxic T lymphocytes (CTL), we used CMV infected GBM cell lines in cytotoxicity assays with human leukocyte antigen partially matched CMV CTL. Lysis of CMV infected GBM tumor cells was accentuated by pre-treating these cell lines with either the demethylating agent decitabine or interferon-γ, both of which were shown to increase MHC Class I and II expression on tumor cells in vitro. These studies confirm the presence of CMV pp65 or IE1 on approximately half of GBM, with the possibility that CMV positive tumor cells can be recognized by CMV pp65/IE1 specific T cells.
Literatur
1.
Zurück zum Zitat Davis FG et al (2001) Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups. Neuro Oncol 3(3):152–158PubMed Davis FG et al (2001) Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups. Neuro Oncol 3(3):152–158PubMed
2.
Zurück zum Zitat Surawicz TS et al (1998) Brain tumor survival: results from the National Cancer Data Base. J Neurooncol 40(2):151–160PubMedCrossRef Surawicz TS et al (1998) Brain tumor survival: results from the National Cancer Data Base. J Neurooncol 40(2):151–160PubMedCrossRef
3.
Zurück zum Zitat Zhang JG et al (2007) Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics. Clin Cancer Res 13(2 Pt 1):566–575PubMedCrossRef Zhang JG et al (2007) Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics. Clin Cancer Res 13(2 Pt 1):566–575PubMedCrossRef
4.
Zurück zum Zitat Saikali S et al (2007) Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy. J Neurooncol 81(2):139–148PubMedCrossRef Saikali S et al (2007) Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy. J Neurooncol 81(2):139–148PubMedCrossRef
5.
Zurück zum Zitat Sampson JH et al (1996) Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the “immunologically privileged” central nervous system. Proc Natl Acad Sci USA 93(19):10399–10404PubMedCrossRef Sampson JH et al (1996) Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the “immunologically privileged” central nervous system. Proc Natl Acad Sci USA 93(19):10399–10404PubMedCrossRef
6.
Zurück zum Zitat Yu JS et al (2001) Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61(3):842–847PubMed Yu JS et al (2001) Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61(3):842–847PubMed
7.
Zurück zum Zitat Mitchell DA, Fecci PE, Sampson JH (2008) Immunotherapy of malignant brain tumors. Immunol Rev 222:70–100PubMedCrossRef Mitchell DA, Fecci PE, Sampson JH (2008) Immunotherapy of malignant brain tumors. Immunol Rev 222:70–100PubMedCrossRef
8.
Zurück zum Zitat Liau LM et al (2005) Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 11(15):5515–5525PubMedCrossRef Liau LM et al (2005) Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 11(15):5515–5525PubMedCrossRef
9.
Zurück zum Zitat Merchant RE et al (1988) Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor. Neurosurgery 23(6):725–732PubMedCrossRef Merchant RE et al (1988) Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor. Neurosurgery 23(6):725–732PubMedCrossRef
10.
Zurück zum Zitat Lillehei KO et al (1991) Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy. Neurosurgery 28(1):16–23PubMedCrossRef Lillehei KO et al (1991) Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy. Neurosurgery 28(1):16–23PubMedCrossRef
11.
Zurück zum Zitat Dillman RO et al (2004) Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. J Immunother 27(5):398–404PubMedCrossRef Dillman RO et al (2004) Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. J Immunother 27(5):398–404PubMedCrossRef
12.
Zurück zum Zitat Serraino D et al (2005) Infection with Epstein-Barr virus and cancer: an epidemiological review. J Biol Regul Homeost Agents 19(1–2):63–70PubMed Serraino D et al (2005) Infection with Epstein-Barr virus and cancer: an epidemiological review. J Biol Regul Homeost Agents 19(1–2):63–70PubMed
13.
Zurück zum Zitat Eiben GL et al (2003) Cervical cancer vaccines: recent advances in HPV research. Viral Immunol 16(2):111–121PubMedCrossRef Eiben GL et al (2003) Cervical cancer vaccines: recent advances in HPV research. Viral Immunol 16(2):111–121PubMedCrossRef
14.
Zurück zum Zitat Bosch FX et al (2005) Epidemiology of hepatocellular carcinoma. Clin Liver Dis 9(2):191–211, vPubMedCrossRef Bosch FX et al (2005) Epidemiology of hepatocellular carcinoma. Clin Liver Dis 9(2):191–211, vPubMedCrossRef
15.
Zurück zum Zitat Vilchez RA, Butel JS (2003) Simian virus 40 and its association with human lymphomas. Curr Oncol Rep 5(5):372–379PubMedCrossRef Vilchez RA, Butel JS (2003) Simian virus 40 and its association with human lymphomas. Curr Oncol Rep 5(5):372–379PubMedCrossRef
16.
Zurück zum Zitat Harkins L et al (2002) Specific localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer. Lancet 360(9345):1557–1563PubMedCrossRef Harkins L et al (2002) Specific localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer. Lancet 360(9345):1557–1563PubMedCrossRef
17.
Zurück zum Zitat Cobbs CS et al (2002) Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res 62(12):3347–3350PubMed Cobbs CS et al (2002) Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res 62(12):3347–3350PubMed
18.
Zurück zum Zitat Samanta M et al (2003) High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. J Urol 170(3):998–1002PubMedCrossRef Samanta M et al (2003) High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. J Urol 170(3):998–1002PubMedCrossRef
19.
Zurück zum Zitat Mitchell DA et al (2008) Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol 10(1):10–18PubMedCrossRef Mitchell DA et al (2008) Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol 10(1):10–18PubMedCrossRef
20.
Zurück zum Zitat Scheurer ME et al (2008) Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathol 116(1):79–86PubMedCrossRef Scheurer ME et al (2008) Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathol 116(1):79–86PubMedCrossRef
21.
Zurück zum Zitat Poltermann S et al (2006) Lack of association of herpesviruses with brain tumors. J Neurovirol 12(2):90–99PubMedCrossRef Poltermann S et al (2006) Lack of association of herpesviruses with brain tumors. J Neurovirol 12(2):90–99PubMedCrossRef
22.
Zurück zum Zitat Lau SK et al (2005) Lack of association of cytomegalovirus with human brain tumors. Mod Pathol 18(6):838–843PubMedCrossRef Lau SK et al (2005) Lack of association of cytomegalovirus with human brain tumors. Mod Pathol 18(6):838–843PubMedCrossRef
23.
Zurück zum Zitat Cinatl J et al (2008) Oncomodulatory signals by regulatory proteins encoded by human cytomegalovirus: a novel role for a viral infection in tumor progression. FEMS Microbiol Rev 28:59–77CrossRef Cinatl J et al (2008) Oncomodulatory signals by regulatory proteins encoded by human cytomegalovirus: a novel role for a viral infection in tumor progression. FEMS Microbiol Rev 28:59–77CrossRef
24.
Zurück zum Zitat Hagemeier C et al (1994) Functional interaction between the HCMV IE2 transactivator and the retinoblastoma protein. EMBO J 13(12):2897–2903PubMed Hagemeier C et al (1994) Functional interaction between the HCMV IE2 transactivator and the retinoblastoma protein. EMBO J 13(12):2897–2903PubMed
25.
Zurück zum Zitat Fortunato EA et al (1997) Identification of domains within the human cytomegalovirus major immediate-early 86-kilodalton protein and the retinoblastoma protein required for physical and functional interaction with each other. J Virol 71(11):8176–8185PubMed Fortunato EA et al (1997) Identification of domains within the human cytomegalovirus major immediate-early 86-kilodalton protein and the retinoblastoma protein required for physical and functional interaction with each other. J Virol 71(11):8176–8185PubMed
26.
Zurück zum Zitat Tsai HL et al (1996) Human cytomegalovirus immediate-early protein IE2 tethers a transcriptional repression domain to p53. J Biol Chem 271(7):3534–3540PubMedCrossRef Tsai HL et al (1996) Human cytomegalovirus immediate-early protein IE2 tethers a transcriptional repression domain to p53. J Biol Chem 271(7):3534–3540PubMedCrossRef
27.
Zurück zum Zitat Bao L et al (2008) Expansion of cytomegalovirus pp65 and IE-1 specific cytotoxic T lymphocytes for cytomegalovirus-specific immunotherapy following allogeneic stem cell transplantation. Biol Blood Marrow Transplant 14(10):1156–1162PubMedCrossRef Bao L et al (2008) Expansion of cytomegalovirus pp65 and IE-1 specific cytotoxic T lymphocytes for cytomegalovirus-specific immunotherapy following allogeneic stem cell transplantation. Biol Blood Marrow Transplant 14(10):1156–1162PubMedCrossRef
28.
Zurück zum Zitat Sun Q et al (2000) B lymphoblastoid cell lines as efficient APC to elicit CD8+ T cell responses against a cytomegalovirus antigen. J Immunol 165(7):4105–4111PubMed Sun Q et al (2000) B lymphoblastoid cell lines as efficient APC to elicit CD8+ T cell responses against a cytomegalovirus antigen. J Immunol 165(7):4105–4111PubMed
29.
Zurück zum Zitat Yang I et al (2004) Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-alpha and interferon-gamma treatment of human glioblastoma multiforme. J Neurosurg 100(2):310–319PubMedCrossRef Yang I et al (2004) Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-alpha and interferon-gamma treatment of human glioblastoma multiforme. J Neurosurg 100(2):310–319PubMedCrossRef
30.
Zurück zum Zitat Read SB et al (2003) Human alloreactive CTL interactions with gliomas and with those having upregulated HLA expression from exogenous IFN-gamma or IFN-gamma gene modification. J Interferon Cytokine Res 23(7):379–393PubMedCrossRef Read SB et al (2003) Human alloreactive CTL interactions with gliomas and with those having upregulated HLA expression from exogenous IFN-gamma or IFN-gamma gene modification. J Interferon Cytokine Res 23(7):379–393PubMedCrossRef
31.
Zurück zum Zitat Serrano A et al (2001) Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2′-deoxycytidine treatment. Int J Cancer 94(2):243–251PubMedCrossRef Serrano A et al (2001) Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2′-deoxycytidine treatment. Int J Cancer 94(2):243–251PubMedCrossRef
32.
Zurück zum Zitat Ogura T et al (1986) Human cytomegalovirus persistent infection in a human central nervous system cell line: production of a variant virus with different growth characteristics. J Gen Virol 67(Pt 12):2605–2616PubMedCrossRef Ogura T et al (1986) Human cytomegalovirus persistent infection in a human central nervous system cell line: production of a variant virus with different growth characteristics. J Gen Virol 67(Pt 12):2605–2616PubMedCrossRef
33.
Zurück zum Zitat Luo MH, Fortunato EA (2007) Long-term infection and shedding of human cytomegalovirus in T98G glioblastoma cells. J Virol 81(19):10424–10436PubMedCrossRef Luo MH, Fortunato EA (2007) Long-term infection and shedding of human cytomegalovirus in T98G glioblastoma cells. J Virol 81(19):10424–10436PubMedCrossRef
34.
Zurück zum Zitat Sabatier J et al (2005) Detection of human cytomegalovirus genome and gene products in central nervous system tumours. Br J Cancer 92(4):747–750PubMedCrossRef Sabatier J et al (2005) Detection of human cytomegalovirus genome and gene products in central nervous system tumours. Br J Cancer 92(4):747–750PubMedCrossRef
35.
Zurück zum Zitat Staras SA et al (2006) Seroprevalence of cytomegalovirus infection in the United States, 1988–1994. Clin Infect Dis 43(9):1143–1151PubMedCrossRef Staras SA et al (2006) Seroprevalence of cytomegalovirus infection in the United States, 1988–1994. Clin Infect Dis 43(9):1143–1151PubMedCrossRef
36.
Zurück zum Zitat Boeke CE et al (2008) CMV antibody prevalence and seroincidence in plateletpheresis donors. J Clin Apher 23(2):63–65PubMedCrossRef Boeke CE et al (2008) CMV antibody prevalence and seroincidence in plateletpheresis donors. J Clin Apher 23(2):63–65PubMedCrossRef
37.
Zurück zum Zitat Thurner B et al (1999) Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190(11):1669–1678PubMedCrossRef Thurner B et al (1999) Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190(11):1669–1678PubMedCrossRef
38.
Zurück zum Zitat Coulie PG et al (2002) Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen. Immunol Rev 188:33–42PubMedCrossRef Coulie PG et al (2002) Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen. Immunol Rev 188:33–42PubMedCrossRef
39.
Zurück zum Zitat Ho WY et al (2006) In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naive repertoire. J Immunol Methods 310(1–2):40–52PubMedCrossRef Ho WY et al (2006) In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naive repertoire. J Immunol Methods 310(1–2):40–52PubMedCrossRef
40.
Zurück zum Zitat Borysiewicz LK et al (1988) Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses. J Exp Med 168(3):919–931PubMedCrossRef Borysiewicz LK et al (1988) Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses. J Exp Med 168(3):919–931PubMedCrossRef
41.
Zurück zum Zitat Liu YN, Kari B, Gehrz RC (1988) Human immune responses to major human cytomegalovirus glycoprotein complexes. J Virol 62(3):1066–1070PubMed Liu YN, Kari B, Gehrz RC (1988) Human immune responses to major human cytomegalovirus glycoprotein complexes. J Virol 62(3):1066–1070PubMed
43.
Zurück zum Zitat Oshiro S et al (2000) Response of MHC class-1 antigen on rat glioma cells to cytokines. Anticancer Res 20(1C):605–610PubMed Oshiro S et al (2000) Response of MHC class-1 antigen on rat glioma cells to cytokines. Anticancer Res 20(1C):605–610PubMed
44.
Zurück zum Zitat Piguet V et al (1986) Heterogeneity of the induction of HLA-DR expression by human immune interferon on glioma cell lines and their clones. J Natl Cancer Inst 76(2):223–228PubMed Piguet V et al (1986) Heterogeneity of the induction of HLA-DR expression by human immune interferon on glioma cell lines and their clones. J Natl Cancer Inst 76(2):223–228PubMed
45.
Zurück zum Zitat Wen PY, Lampson MA, Lampson LA (1992) Effects of gamma-interferon on major histocompatibility complex antigen expression and lymphocytic infiltration in the 9L gliosarcoma brain tumor model: implications for strategies of immunotherapy. J Neuroimmunol 36(1):57–68PubMedCrossRef Wen PY, Lampson MA, Lampson LA (1992) Effects of gamma-interferon on major histocompatibility complex antigen expression and lymphocytic infiltration in the 9L gliosarcoma brain tumor model: implications for strategies of immunotherapy. J Neuroimmunol 36(1):57–68PubMedCrossRef
46.
Zurück zum Zitat Mitchell D et al (2008) Efficacy of a phase II vaccine targeting cytomegalovirus antigens in newly-diagnosed GBM. J Clin Oncol 26:2042 Mitchell D et al (2008) Efficacy of a phase II vaccine targeting cytomegalovirus antigens in newly-diagnosed GBM. J Clin Oncol 26:2042
47.
Zurück zum Zitat Prins RM, Cloughesy TF, Liau LM (2008) Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N Engl J Med 359(5):539–541PubMedCrossRef Prins RM, Cloughesy TF, Liau LM (2008) Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N Engl J Med 359(5):539–541PubMedCrossRef
48.
Zurück zum Zitat Bao L, Sun Q, Lucas KG (2007) Rapid generation of CMV pp65-specific T cells for immunotherapy. J Immunother (1997) 30(5):557–561CrossRef Bao L, Sun Q, Lucas KG (2007) Rapid generation of CMV pp65-specific T cells for immunotherapy. J Immunother (1997) 30(5):557–561CrossRef
Metadaten
Titel
The detection of CMV pp65 and IE1 in glioblastoma multiforme
verfasst von
Kenneth G. Lucas
Lei Bao
Richard Bruggeman
Kimberly Dunham
Charles Specht
Publikationsdatum
01.06.2011
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 2/2011
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-010-0383-6

Weitere Artikel der Ausgabe 2/2011

Journal of Neuro-Oncology 2/2011 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.